Loading...
Clostridioides difficile-induced diarrhoea following dasatinib therapy
Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However, Clostridioides difficile infections (CDIs) in the context of dasatinib therapy, without a...
Saved in:
| Published in: | BMJ Case Rep |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BMJ Publishing Group
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7813327/ https://ncbi.nlm.nih.gov/pubmed/33462050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-239394 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|